Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Spire type actin nucleation factor 2 (SPIRE2) is a cytoskeletal regulator and actin-binding protein characterized by multiple WASP homology 2 (WH2) domains, enabling actin nucleation by organizing actin monomers into a configuration favorable for filament assembly[2][6]. SPIRE2 remains associated with the pointed end of nascent filaments, facilitates intracellular vesicle transport, and is essential for processes such as spindle positioning during meiosis and DNA repair after double-strand breaks[1][5][6]. SPIRE2 coordinates actin assembly with formin-family proteins, participating in the formation of actin tracks at organelle membranes, and is involved in cytoskeletal dynamics across diverse cellular compartments[3][6]. Deficiency in SPIRE2 disrupts essential cytoskeletal processes, impacting events such as oogenesis, actin mesh formation, and chromatin movement during DNA repair[4][5]. While it plays critical biological roles, SPIRE2 is not considered a classical therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Spire type actin nucleation factor 2 (SPIRE2).